Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

March 2018 • Volume 17 • Number 3

Highlights of This Issue 589

REVIEW

SMALL MOLECULE THERAPEUTICS

LARGE MOLECULE THERAPEUTICS

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

Table of Contents

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Internalization of the antibody against a tumor antigen is one of the key features in developing an antibody-drug conjugate (ADC) therapeutic. Bhakta and colleagues identify GFRA1 as an excellent luminal A breast cancer ADC target. The image depicts the internalization of anti-GFRA1 antibody-Alexa488 conjugate (green) upon binding to HEK293 cells expressing GFRA1 protein. It's co-localization (yellow) with LAMP2, a late endosomal/lysosmal marker (red) is observed. Image Courtesy: Coenraad Kuijl.